Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Archive > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 August;56(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 August;56(4):375-84

CURRENT ISSUE   ARCHIVE   EPUB AHEAD OF PRINT   MOST READ   eTOC


THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 August;56(4):375-84

 

    ORIGINAL ARTICLES

Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications

Evangelista L. 1, Baretta Z. 2, Vinante L. 1, Bezzon E. 3, De Carolis V. 1, Cervino A. R. 1, Gregianin M. 1, Ghiotto C. 2, Saladini G. 1, Pomerri F. 3, Muzzio P. C. 3

1 Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto (IOV – IRCCS), Padua, Italy;
2 Oncology Unit 2, Istituto Oncologico Veneto (IOV – IRCCS), Padua, Italy;
3 Radiology Oncology, Istituto Oncologico Veneto (IOV – IRCCS), Padua, Italy

AIM: The purpose of the study was to assess the comparison of 18F-FDG PET/CT and CT in patients with breast cancer (BC) already treated with primary therapy, in evaluating the diagnostic and prognostic values.
METHODS: We retrospectively studied 190 patients (187 women and 3 men, mean age 61±11 years) with previous BC (all stages) after surgery and other primary treatments. They underwent within three months CT and 18F-FDG PET/CT examinations for the evaluation of disease status. Disease relapse was confirmed by clinical evaluation and/or radiological findings. Survival curves of disease-free survival (DFS) and overall survival (OS) were computed using Kaplan-Meier method. Cox analysis regression was used to determine predictive factors of DFS and OS.
RESULTS: Of the overall 190 patients, 82 (43%) had evidence of clinical and/or imaging disease relapse, while 108 (57%) did not. Sensitivity, specificity, negative predictive and positive predictive values for disease relapse or progression were of 89% vs. 77%, 73% vs. 53%, 90% vs. 75% and 72% vs. 55%, respectively for PET/CT and CT. DFS curves were significantly different in patients with both negative and positive PET/CT and CT (log-rank test 33.6; P<0.0001 and 12.7; P=0.003, respectively). OS curves were similar in patients with positive/negative PET/CT and CT (P=NS). By both univariate and multivariate Cox regression analysis positive PET/CT was found to be related to the disease recurrence (HR 0.18 and 0.20, both P<0.0001, respectively).
CONCLUSION: PET/CT is more accurate than CT in identification of disease relapse in a large population of BC patients. In women at high-risk of recurrence, PET/CT imaging can provide the early detection of BC metastases, tailoring a proper treatment.

language: English


FULL TEXT  REPRINTS

top of page